Judge dismisses Plan B suit
This article was originally published in The Tan Sheet
Executive Summary
A judge in the U.S. District Court for the District of Columbia dismisses a case challenging FDA's OTC approval of Barr Pharmaceuticals' Plan B emergency contraceptive for consumers 18 years of age and older. Judge John Bates ruled March 4 the court "has no jurisdiction" in the case brought by several groups including the Association of American Physicians and Surgeons and Concerned Women for America, in part because they "failed to exhaust their administrative options" before bringing the case to court. The groups unsuccessfully argued that the OTC approval of Plan B put consumers at risk because they did not visit their health care providers, placed pharmacists at increased liability risk and unfairly increased physician competition, among other complaints...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.